Clinical Trials Using CD30 CAR-expressing Autologous T Lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying CD30 CAR-expressing Autologous T Lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • CD30 CAR T Cells with or without Cyclophosphamide and Fludarabine in Treating Participants with Relapsed or Refractory CD30 Positive Lymphoma

    This phase I trial studies the side effects and best dose of CD30 CAR-expressing autologous T lymphocytes (CAR T cells) when given together with or without cyclophosphamide and fludarabine in treating participants with CD30 positive lymphoma that has come back or does not respond to treatment. CD30 CAR-expressing autologous T lymphocytes combine antibodies and T cells. Antibodies are proteins that protect the body from diseases caused by germs or toxic substances. They work by binding those germs or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cancer cells or cells that are infected with germs. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD30 CAR-expressing autologous T lymphocytes, cyclophosphamide, and fludarabine together may work better in treating participants with CD30 positive lymphoma.
    Location: 3 locations

  • CD30 CAR-expressing Autologous T Lymphocytes in Preventing Relapse after High Dose Chemotherapy and Stem Cell Transplant in Patients with CD30+ Lymphoma

    This phase I trial studies the side effects and best dose of CD30 chimeric antigen receptor (CAR)-expressing autologous T lymphocytes when given after high dose chemotherapy and stem cell transplant to patients with cluster of differentiation (CD)30+ lymphoma. T-cells are special infection fighting blood cells that can kill tumor cells. The T-cells given in this study will come from the patient and will have a new gene put in them that makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of cells called CD30. Attaching anti-CD30 antibody to T-cells may help the T-cells to find cancer cells that have developed a way to hide from the immune system. Giving T-cells with anti-CD30 antibody attached may help restore immune system function and prevent relapse in patients with CD30+ lymphoma that has come back.
    Location: 2 locations

  • CD30 Receptor-Activated T-cells in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    This phase Ib / II trial studies the side effects of and how well CD30 receptor-activated T-cells work in treating patients with CD30+ Hodgkin lymphoma or non-Hodgkin lymphoma that has come back after a period of treatment or does not respond to treatment. T-cells are special infection fighting blood cells that can kill cancer cells. The T-cells given in this study will come from the patient and will have a new gene put in them that makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of cells called CD30. Attaching anti-CD30 antibody to T-cells may help the T-cells to find cancer cells that have developed a way to hide from the immune system. Giving T-cells with anti-CD30 antibody attached may help restore immune system function and prevent relapse in patients with CD30+ Hodgkin lymphoma or non-Hodgkin lymphoma.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina